Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR and Ipilimumab in Oligometastatic Melanoma
NCT02107755Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2014
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Sep 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02107755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107755.